Ligand-receptor signaling with the epidermal growth factor (EGF) family of growth factors in the uterus and embryo is considered to be important for implantation. The EGF family includes EGF, transforming growth factor-␣, heparin binding-EGF, amphiregulin, betacellulin, epiregulin, and heregulins, whereas the receptor family (the erbB genes) consists of erbB1 (EGF-receptor, EGF-R), erbB2, erbB3, and erbB4. Interactions of uterine EGF-R with EGF-like ligands have been examined, but limited information is available regarding the status of other receptor subtypes. Thus, we examined the expression of the erbB2 gene in the mouse uterus during the periimplantation period (days 1-8 of pregnancy) and after 17␤-estradiol and/or progesterone stimulation. Northern blot hybridization detected two transcripts (ϳ4.0 and 5.0 kb) of erbB2 messenger RNA (mRNA) in day 1-8 uterine polyadenylated RNA samples. In situ hybridization experiments showed unique uterine cell-specific erbB2 mRNA distribution. On days 1-4, unlike the full-length erbB1 mRNA which is not expressed in the uterine epithelium, the erbB2 mRNA was detected primarily in epithelial cells; the day 1 uterus showed the highest accumulation. On day 5, the epithelium and the decidualizing stromal cells around the implanting blastocyst exhibited accumulation of this mRNA. On days 6 -8, the accumulation persisted in the epithelium at both the implantation and interimplantation sites in addition to modest levels of signals in the secondary decidual zone. On days 7 and 8, accumulation of the erbB2 mRNA was also prominent in the trophoblastic giant cells. Western blotting detected a predicted protein of 185 kDa in day 4 uterine membrane preparations. Results of immunocytochemistry demonstrated colocalization of the erbB2 protein with its mRNA in the periimplantation uterus. The uterine ErbB2 underwent phosphorylation by several members of the EGF family. Treatment of adult ovariectomized mice with 17␤-estradiol, but not progesterone, up-regulated the expression of the erbB2 mRNA by more than 3.5-fold, as determined by quantitative reverse transcription-PCR, and this increase was limited to the epithelium, as revealed by in situ hybridization. Collectively, the results place ErbB2 as a potential candidate receptor subtype for interaction with the EGFrelated ligands in epithelial cell proliferation/differentiation during the preimplantation period and stromal cell proliferation/decidualization during the postimplantation period. (Endocrinology 138: 1328 -1337, 1997) S YNCHRONIZED development of the embryo to the blastocyst stage and preparation of the uterus to the receptive state are essential for implantation (1, 2). The establishment of the receptive uterus is achieved by the coordinated actions of progesterone (P 4 ) and estrogen in a temporal and cell type-specific manner (3). In the mouse, the uterus on days 1 and 2 of pregnancy is under the influence of the preovulatory estrogen surge that directs proliferation of the epithelium. In contrast, increasing levels of P 4 from the newly formed corpus lutea result in the switching of proliferation from the epithelium to the stroma on day 3 of pregnancy. This is further stimulated by preimplantation ovarian estrogen secretion on day 4 (3). Similar steroid hormonal modulation of uterine cell proliferation can be attained experimentally. Thus, in the adult ovariectomized mouse uterus, estrogen stimulates proliferation of the epithelium, whereas this process in the stroma requires both P 4 and estrogen (3). However, the molecular signaling that directs estrogenand/or P 4 -mediated proliferation and/or differentiation of specific uterine cell types required for implantation is poorly understood. The regulated expression of several growth factors and their receptors in the uterus and embryo during the periimplantation period or under steroid hormonal stimulation suggests that these growth factors could serve as local mediators of steroid hormone actions (4 -16). In this respect, the roles of the epidermal growth factor (EGF) family of growth factors in uterine biology and implantation have been studied more extensively than those of other polypeptide growth factors.
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The EGF family includes EGF, transforming growth factor-␣ (TGF␣), amphiregulin (AR), heparin binding-EGF (HB-EGF), betacellulin, epiregulin, and heregulins/neu differentiation factors (NDFs) (17) (18) (19) (20) (21) (22) (23) . In the rodent, these ligands can interact with the receptor subtypes of the erbB gene family. This family is comprised of four receptor tyrosine kinases: ErbB1 (EGF-R), ErbB2, ErbB3, and ErbB4. They share a common structural feature, but differ in their ligand specificities and kinase activities (24 -26) . EGF, TGF␣, HB-EGF, AR, betacellulin, and epiregulin can interact either with ErbB1 via homodimerization or with other ErbB members through heterodimerization (27, 28) . In this respect, the NDFs, which can stimulate phosphorylation of the 185-kDa product of the erbB2 gene (23) , require direct binding to either erbB3 or erbB4 (29) . Thus, cross-talk between the receptor subtypes with various ligands can serve as a potential signaling mechanism (27, 28) .
The expression patterns of EGF, TGF␣, AR, and HB-EGF in the uterus during the periimplantation period and their responsiveness to sex steroid hormones have been examined (4, 6, 8, 11) . Overall, the results suggest that AR may be involved in uterine preparation for implantation, whereas HB-EGF could interact with blastocyst ErbB1/ EGF-R for the attachment reaction (6, 30) . The role of TGF␣ in implantation is questioned, because female mice deficient in TGF␣ are apparently fertile (31, 32) . These studies also suggested that uterine cell proliferation or differentiation by steroid hormones is mediated locally by these growth factors. EGF was shown to bind to uterine epithelial cells and induce their proliferation both in vitro and in vivo (33, 34) . Thus, it was suggested that EGF-like growth factors can influence epithelial cell functions directly. However, more rigorous studies document that mouse uterine epithelial cells exhibit little or no expression of the functional full-length ErbB1/EGF-R, although a truncated form is expressed in these cell (7, 35) . This controversial issue of how EGF mediates epithelial cell proliferation could be resolved if it is found that epithelial cell proliferation directed by EGF-like ligands or steroid hormones is mediated either indirectly via stromal cell ErbB1 in a paracrine manner or via other members of the ErbB family in epithelial cells. However, little or no information is available regarding the status of these receptor subtypes in the mouse uterus.
As the nature of ligand-receptor signaling with EGF-like growth factors is complex and varies according to the cell types and receptor subtypes expressed (36) , it is important to examine the expression profiles of the erbB gene family in the uterus to better understand their roles in uterine biology and implantation. In this investigation, we examined whether ErbB2 could be a candidate mediator of signaling by EGF-like growth factors in the uterus, as TGF␣, HB-EGF, and AR, which are expressed in the uterus, have been shown to induce heterodimerization of erbB1 and erbB2, and the later is considered an integral subunit of this heterodimerization (36, 37) . Thus, we cloned the mouse erbB2 complementary DNA (cDNA) and examined its temporal and cell type-specific expression in the mouse uterus during the periimplantation period and its modulation by ovarian steroid hormones in ovariectomized mice. Receptor phosphorylation studies were performed to determine whether uterine ErbB2 is functional. The results establish that unlike the erbB1/EGF-R gene, the erbB2 gene is expressed in the preimplantation or estrogentreated uterine epithelium and in the deciduum during the postimplantation period. The findings suggest that ErbB2 is a potential mediator of signaling by EGF-related growth factors in the mouse uterus.
Materials and Methods

Growth factors and antibodies
The receptor grade mouse EGF and recombinant human betacellulin were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY), and R&D Systems (Minneapolis, MN), respectively. Human recombinant HB-EGF was kindly provided by Judith Abraham (Scios Nova, Mountain View, CA) and human NDF␣1 and NDF␤1 were generous gifts of D. Wen (Amgen, Thousand Oaks, CA). The antibody used in phosphorylation studies was antihuman Neu polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Animals and tissue preparation
CD-1 mice (Charles River Laboratory, Raleigh, NC) were housed in the animal care facility at the University of Kansas Medical Center according to NIH and institutional guidelines for the care of laboratory animals. Adult female mice (20 -25 g; 48 -60 days old) were mated with fertile males of the same strain. The morning when a vaginal plug was found was designated day 1 of pregnancy. Mice were killed between 0830 -0900 h on days 1-8 of pregnancy. Whole uteri were collected on days 1-7 of pregnancy, whereas the deciduum was surgically separated on day 8. Early implantation sites on day 5 (0830 -0900 h) were visualized by iv injections (0.1 ml/mouse) of a Chicago blue B dye solution (1% in saline) and killed 5 min later to identify the blue bands (implantation sites) along the uterus (2) .
To determine the effects of estrogen and P 4 , mice were ovariectomized without regard to the stage of the estrous cycle and rested for 2 weeks. They were given an injection of 17␤-estradiol (E 2 ; 250 ng/mouse; Sigma Chemical Co, St. Louis, MO), P 4 (2 mg/mouse; Sigma), or a combination of the same doses of P 4 and E 2 . All steroids were dissolved in sesame oil and injected sc (0.1 ml/mouse). The control animals received the vehicle (0.1 ml/mouse) only. Mice were killed at different times after hormone injections, and their uteri were collected for analysis.
Cloning and sequencing of the mouse erbB2 partial cDNA
Reverse transcription-PCR (RT-PCR) was used to generate the erbB2 partial cDNA clone. RT-PCR conditions were essentially as described previously by us (10) . Oligonucleotide primers were synthesized based on the cDNA sequence of the human erbB2 gene for the cytoplasmic domain (38) . The primers were 5Ј-GCTCCCCATATGTCTCCCGC-3Ј (sense) and 5Ј-GCCGCTCCCCCTTTTCCAGC-3Ј (antisense). The sense strand primer corresponds to 2483-2502 nucleotides (nt), whereas the antisense strand primer encompasses 2852-2971 nt of the human erbB2 gene. Day 4 pregnant mouse uterine total RNA (1 g) was reverse transcribed using the antisense primer as previously described (10) . RT products (3 l) were amplified by PCR for 45 cycles using the cycle parameters: 94 C, 1.5 min; 55 C, 2 min; 72 C, 2.5 min. The predicted RT-PCR product (489 bp) was analyzed by gel electrophoresis, and its authenticity was verified by Southern blot hybridization using a 32 P end-labeled internal primer derived from the human erbB2 sequence. RT-PCR product was cloned into pCR-Script SK ϩ cloning vector (Stratagene, La Jolla, CA). Several colonies were analyzed by restriction digestion, and finally, the nt sequence of one clone was determined on both strands by the dideoxy nt chain termination method (39) and the Sequenase version 2.0 kit (U.S. Biochemical, Cleveland, OH).
Hybridization probes
For Northern hybridization, 32 P-labeled antisense complementary RNA (cRNA) probes were generated, whereas for in situ hybridization, sense and antisense 35 S-labeled cRNA probes were generated using the appropriate polymerases. Probes had specific activities of about 2 ϫ 10 9 dpm/g.
Northern blot hybridization
Total RNAs were extracted from whole uteri pooled from 10 -15 mice on the indicated days of pregnancy by a modified guanidine thiocyanate procedure (6, 7) . Polyadenylated [poly (A) ϩ ] RNAs were isolated from total RNAs by oligo (deoxythymidine)-cellulose column chromatogra-phy (40) . Poly(A) ϩ RNA (2 g) was denatured, separated by formaldehyde-agarose gel electrophoresis, transferred to nylon membranes, and cross-linked by UV irradiation (Spectrolinker, XL-1500, Spectronics Corp., Westbury, NY). The blots were prehybridized, hybridized, and washed as described previously (6) . After hybridization, the blots were washed under stringent conditions, and the hybrids were detected by autoradiography (6) . The blots were stripped and rehybridized with ␤-actin probe as described previously (7).
In situ hybridization
In situ hybridization was performed as described previously (6) . Uteri were cut into 4-to 6-mm pieces and flash-frozen in freon. Frozen sections (11 m) from days 1-4 or days 5-8 of pregnancy were mounted onto poly-l-lysine-coated slides, fixed in cold 4% paraformaldehyde solution in PBS, acetylated, and hybridized at 45 C for 4 h in 50% formamide hybridization buffer containing the 35 S-labeled antisense cRNA probe. After hybridization and washing, the sections were incubated with ribonuclease A (RNase A; 20 g/ml) at 37 C for 15 min. RNase A-resistant hybrids were detected by autoradiography using Kodak NTB-2 liquid emulsion (Eastman Kodak, Rochester, NY). Parallel sections hybridized with the sense probe served as negative controls. Slides were poststained with hematoxylin and eosin.
Construction of competitive templates for erbB2 and ribosomal protein L7 (rPL7)
To generate the competitive templates for quantitation of uterine erbB2 and rPL7 messenger RNAs (mRNAs) (41, 42), a nonspecific DNA fragment (185-bp SspI fragment obtained from PGEM 72f ϩ vector) was ligated at the StyI site of the mouse erbB2 cDNA or at the PstI site of the mouse rPL7 cDNA. These competitive templates were used to quantitate mRNAs for these genes. rPL7 served as a housekeeping gene (43) .
RT-PCR quantitation of erbB2 mRNA after steroid hormone treatments
The oligonucleotide primers were synthesized based on the sequence of the cloned mouse erbB2 cDNA as follows: sense strand, 5Ј-TCTGC-CTGACATCCACAGTG-3Ј; and antisense strand, 5Ј-AATAGATTC-CAATGCCATCC-3Ј. The primers for mouse rPL7 clone were as follows: sense strand, 5Ј-TCAATGGAGTAAGCCCAAAG-3Ј; and antisense strand, 5Ј-CAAGAGACCGAGCAATCAAG-3Ј. Uterine total RNAs (8.75 g) from ovariectomized mice injected with oil, E 2 , P 4 , or E 2 plus P 4 were subjected to RT reactions using the antisense primers in a total volume of 14 l as previously described (10) . A constant amount of the sample cDNA (one tenth of the total RT product) and increasing amounts of the mutant template were coamplified by PCR for 35 cycles using the sense and antisense primers for each specific mRNA. The PCR protocol and cycle parameters were same as described above for RT-PCR cloning. The predicted sizes of the sample and mutant DNA templates were 320 and 505 bp for erbB2 and 246 and 431 bp for rPL7, respectively. The products were subjected to 1% agarose gel electrophoresis for Southern blot hybridization using 32 P end-labeled internal primers: 5Ј-ATG-CAGATGGGGGCAAGGTG-3Ј for erbB2 and 5Ј-GATTGCCTTGACA-GATAATTC-3Ј for rPL7. The quantitation of band intensities on the autoradiogram was achieved using densitometric scanning (Personal Densitometric SI, Molecular Dynamics, Sunnyvale, CA). The ratios of band intensities of the sample bands to those of the mutant bands were plotted against the amount of the mutant templates. The amount of sample DNA, reflecting the initial levels of mRNA, was determined from the zero equivalence point on the logarhythmic graph.
Generation of antipeptide antibody to ErbB2
Antipeptide antibodies to ErbB2 were raised in rabbits using a synthetic 14-amino acid peptide representing the cytoplasmic domain of the mouse erbB2 amino acid sequence, 808 -821 (DHVREHRGRLGSQD). S-labeled antisense cRNA probe. RNase-A resistant hybrids were detected by autoradiography after 10 days of exposure. Uterine erbB2 mRNA distribution on days 1 (A and B), 4 (C and D), 5 (E and F), and 8 (G and H) of pregnancy is shown in brightfield (left column) and darkfield (right column) photomicrographs at ϫ40. LE, Luminal epithelium; GE, glandular epithelium; S, stroma; MYO, myometrium; PDZ, primary decidual zone; SDZ, secondary decidual zone; BL, blastocyst. These experiments were repeated using three or four mice for each day of pregnancy examined.
The antipeptide antibodies were affinity purified through Affi-Gel 10 (Bio-Rad Laboratories, Hercules, CA) conjugated with the corresponding peptide (9) and used for Western blot and immunostaining.
Western blotting
The method essentially followed the protocol described by us previously (9) . In brief, day 4 mouse uteri were collected into buffer A [10 mm Tris-HCl (pH 7.4), 250 mm sucrose, 2 mm EGTA, 10 g/ml leupeptin, 20 g/ml phenylmethylsulfonylfluoride, and 10 g/ml aprotinin]. They were homogenized in buffer A and centrifuged at 2,000 rpm for 10 min at 4 C. The supernatants were recentrifuged at 35,000 rpm for 1 h at 4 C. The pellets were resuspended in the same buffer and spun again for 1 h at 35,000 rpm at 4 C. The pellets were then dissolved in buffer B [10 mm Tris-HCl (pH 7.4), 0.15 mm NaCl, 1 mm EGTA, 10 g/ml leupeptin, 20 g/ml phenylmethylsulfonylfluoride, and 10 g/ml aprotinin], and protein concentrations were measured. Aliquots of protein (60 g) were mixed with sample buffer and boiled for 5 min. The samples were run on a 7.5% SDS-polyacrylamide gel under reduced condition. The proteins on the gel were transferred onto a nitrocellulose membrane. The membrane was preincubated with 5% nonfat dry milk in Trisbuffered saline (TBS) for 2 h to block nonspecific binding. The membrane was incubated in antipeptide antibody to ErbB2 overnight at 4 C. The membrane was washed three times for 10 min each in 5% nonfat dry milk in TBS and incubated with goat antirabbit IgG conjugated with horseradish peroxidase (1:15,000) for 1 h. The membrane was again washed three times (10 min each time) in 5% nonfat dry milk in TBS and three times in TBS. Signals were detected with the ECL kit (Amersham, Arlington Heights, IL). As a control, the antipeptide antibody was preneutralized with a 200-fold molar excess of the synthetic peptide that was used as the immunogen.
Immunohistochemistry
Pieces of uteri from day 1-8 pregnant mice were fixed in cold 4% paraformaldehyde in PBS for 2 h, dehydrated, and embedded in paraffin. Paraffin sections (7 m) were mounted onto poly-l-lysine-coated slides, deparaffinized, rehydrated, and washed in PBS. The blocking of nonspecific binding was achieved by incubating sections in 10% normal goat serum for 10 min. The sections were then incubated in the antipeptide antibody overnight at 4 C. Immunostaining was performed using a Zymed-Histostain-SP kit (Zymed Laboratories, San Francisco, CA) containing a biotinylated secondary antibody, a horseradish peroxidase-streptavidin conjugate, and a substrate-chromogen mixture (7). The endogenous peroxidase activity was blocked by 0.23% periodic acid in PBS for 30 sec after incubation with the secondary antibody. Sections were counterstained with hematoxylin. Red deposits indicated the sites of positive immunostaining. As a control, the antipeptide antibody was preneutralized with a 200-fold molar excess of the antigenic peptide.
Phosphorylation of uterine ErbB2
The phosphorylation of ErbB2 was determined in day 5 pregnant uterine membranes using the method described by us previously (6 -8) . Membranes (100 g protein) were suspended in 50 l reaction buffer [50 mm PIPES (pH 7.0), 1 mm MnCl 2 , and 0.1 mm Na vanadate] and preincubated with or without a ligand (100 ng/ml) for 10 min at 4 C. The labeling reaction was initiated by the addition of 5 Ci [␥-
32 P]ATP (1 m) in the presence of 0.1% Triton X-100 and was continued for 2 min at 4 C. The reaction was terminated by the addition of 15 l of an ice-cold mixture of 1 mm ATP and 0.1% BSA, followed by an equal volume of 10% trichloroacetic acid (wt/vol). After incubation on ice for 1 h, the mixture was centrifuged for 5 min in a microcentrifuge at the maximum speed, and the precipitates were collected. The precipitates were washed three times with a mixture of diethylether and ethanol (1:1), and dissolved in 50 l 50 mm Tris buffer (pH 7.5). An equal volume of protein A-Sepharose-ErbB2 antibody conjugate (3 mg:0.4 g) was added to this mixture and incubated for 90 min at 4 C with constant shaking. The protein A-Sepharose-antibody conjugates were washed sequentially with buffer A (50 mm HEPES, 0.1% Triton X-100, 0.1% SDS, and 5 mm EGTA, pH 8.0), buffer B (50 mm HEPES, 0.1% Triton X-100, 0.1% SDS, and 150 mm NaCl, pH 8.0), and buffer C (10 mm Tris-HCl, pH 8.0). The   FIG. 4 . Western blot analysis of the ErbB2 protein in the uterus. Day 4 pregnant uterine membranes were immunoblotted using a rabbit polyclonal antipeptide antibody to ErbB2 (Ab) and preneutralized antibody with the antigenic peptide (Abϩpeptide). A 185-kDa product of immunoreactive ErbB2 (p185 erbB2 ) is indicated. These experiments were repeated four times using independent membrane preparations with similar results. pellets were heated in 1 ϫ SDS sample buffer [62.5 mm Tris (pH 6.8), 2% SDS, 10% glycerol, and 5% ␤-mercaptoethanol] to 100 C for 3 min and centrifuged, and the resultant supernatants were subjected to 10% SDS-PAGE in parallel with mol wt markers. The gel was transferred to nitrocellulose membrane, and the products were visualized by autoradiography.
Results
The erbB2 cDNA sequence
A partial cDNA clone for the mouse ErbB2 was generated by RT-PCR using primers based on the sequence of the human erbB2 cDNA. The amplified cDNA was cloned, sequenced, and used as template for the synthesis of antisense or sense strand erbB2 RNA. The cloned mouse erbB2 cDNA was 486 bp encompassing exons 22-24 (2483-2968 nt of the human erbB2) with corresponding codons 779 -841 nt (Fig. 1) . This region has 90% sequence identity with the human or 95% with the rat erbB2 cDNA (38, 44) . Further, the deduced amino acid sequence of the mouse erbB2 is 98% and 99% homologous with those of the human and rat ErbB2, respectively. The GenBank accession number of this cDNA is U71126.
Northern blot analysis of the erbB2 mRNA in the periimplantation uterus
Steady state levels of the erbB2 mRNA in the periimplantation uterus (days 1-8) were analyzed using a 32 P-labeled antisense cRNA probe (Fig. 2) . Two major transcripts (ϳ4.0 and 5.0 kilobases) were detected in whole uterine RNA samples. The levels of this mRNA were highest on day 1, but did not show much variation thereafter. The significance of two transcripts (4.0 and 5.0 kilobases) of the erbB2 mRNA in the mouse uterus is not yet clear. However, multiple transcripts have also been identified in the human and rat tissues (38, 44) . In addition, in human breast cancer cell lines, a truncated form of ErbB2, generated by alternative RNA splicing, has growth regulatory role (45) . However, no information is yet available about whether a truncated form of ErbB2 is produced in the mouse.
In situ hybridization analysis of the erbB2 mRNA in the periimplantation uterus
In situ hybridization showed a unique cell-specific expression pattern in the periimplantation uterus. During the preimplantation period (days 1-4), the erbB2 mRNA was predominantly detected in the luminal and glandular epithelium (Fig. 3, A-D) . On days 5 and 6 (early postimplantation), the erbB2 mRNA accumulation occurred in the epithelium situated at the implantation or interimplantation regions (Fig. 3, E and F) . In addition, this mRNA accumulated in the stroma surrounding the implanting blastocyst. With the progression of decidualization on days 7 and 8, the remaining luminal epithelium and glands in the interimplantation regions still maintained the erbB2 mRNA accumulation (Fig. 3, G and H) . Around the implanting blastocyst, erbB2 mRNA was localized in the secondary decidual zone at higher abundance. An accumulation of the erbB2 mRNA was also noted in the embryo proper and the trophoblastic giant cells on days 7 and 8.
Western blot analysis of immunoreactive ErbB2 in the uterus
Western blotting experiments using an antipeptide antibody to ErbB2 detected a predicted 185-kDa protein band in the day 4 pregnant uterine membrane preparations. This band was not detected when preneutralized antibody with a 200-fold molar excess of the antigenic peptide was used (Fig. 4) .
Analysis of immunohistochemistry of ErbB2 in the periimplantation uterus
The distribution of the ErbB2 protein in the uterus on days 1-8 was consistent with the localization of its mRNA. Representative immunostaining for days 4 and 5 (implantation site) uterine sections is shown (Fig. 5, A and B) . No positive immunostaining was obtained when sections were incubated with the primary antibody preneutralized with the antigenic peptide (data not shown).
Phosphorylation of ErbB2 in the uterus
To determine whether uterine ErbB2 undergoes phosphorylation in response to EGF-like ligands, day 5 pregnant uterine membranes were pretreated with or without EGF, HB-EGF, NDF-␣1, NDF-␤1, or betacellulin, followed by labeling with [␥-32 P]ATP and immunoprecipitated with an antibody to ErbB2. Autoradiography exhibited the phosphorylation of the p185 erbB2 protein when the samples were challenged with either EGF, HB-EGF, NDFs, or betacellulin, although the levels of induction of phosphorylation by NDFs were lower than those induced by other members (Fig. 6) . No phosphorylated 185-kDa band was detected in the absence of any ligand (control). The specificity of the antibody was confirmed by the detection of the p185 erbB2 product after immunoprecipitation with protein A-Sepharose-ErbB2 antibody conjugate followed by Western blotting; however, immunoprecipitation using normal rabbit IgG did not detect this product in uterine membrane preparations (data not shown). P]ATP. After 2 min of labeling, immunoprecipitations were performed with antibodies to ErbB2. Precipitated proteins were separated by 10% SDS-PAGE, transferred to nitrocellulose membrane, and detected by autoradiography for 3 h. These experiments were repeated three times using independent membrane preparations with similar results.
Quantitation of the erbB2 mRNA in the steroid-treated uterus
A competitive RT-PCR technique was employed to quantitate the mRNA levels in the ovariectomized uteri after treatments with E 2 and/or P 4 . As shown in Fig. 7 and Table  1 , an injection of E 2 induced uterine erbB2 mRNA levels by more than 3.5-fold by 24 h. In contrast, an injection of P 4 alone down-regulated the constitutive erbB2 mRNA levels that were observed in oil-treated uterus. Furthermore, coinjection of P 4 with E 2 antagonized the E 2 induction of uterine erbB2 mRNA levels. The levels of uterine erbB2 mRNA did not fluctuate appreciably at earlier time points after each of these steroid treatments (data not shown). The efficiency of the RT reactions was controlled by measuring the levels of rPL7 mRNA (a housekeeping gene) in each sample (Fig. 8) . The rPL7 mRNA levels did not show much variation after any of the steroid treatments (ϳ4.0 ϫ 10 7 copies/g total RNA).
Cell-specific localization of the erbB2 mRNA in the steroidtreated uterus
In situ hybridization showed that E 2 induction of the erbB2 mRNA was limited to the luminal and glandular epithelium (Fig. 9) . The apparent levels of accumulation in the uterine epithelium after an injection of oil, P 4 , or P 4 and E 2 were consistent with the RT-PCR results (illustration not shown).
FIG. 7.
Quantitation of erbB2 mRNA levels in steroid-treated adult ovariectomized mice. Uterine total RNAs (8.75 g) from ovariectomized mice treated with oil (A; 0.1 ml oil/mouse), E 2 (B; 250 ng/mouse), P 4 (C; 2 mg/mouse), or E 2 plus P 4 (D) were reverse transcribed using an erbB2 mRNA-specific antisense oligo. A constant amount of the sample cDNA (one tenth of the total RT product) and increasing amounts of the competitor template (0.1-312.50 fg) were coamplified by PCR for 35 cycles using the antisense and sense oligos. The products were subjected to Southern blot hybridization using a 32 P-labeled internal oligo. Quantitation of band intensities on the autoradiogram was performed using a densitometry scanner (Molecular Dynamics). The ratios of band intensities of the sample to those of the mutant were plotted against the amount of mutant templates. The amount of sample DNA reflecting the initial levels of mRNA was determined from the zero equivalence point of the logarhythmic graph. These experiments were performed in triplicate, and representative plots are shown.
Discussion
The erbB2 gene was first characterized as a homolog of the rat neu oncogene and identified in ethylnitrosourea-induced rat neuroglioblastomas (46) . Its striking similarity with the erbB1 gene placed erbB2 as a putative receptor for EGFrelated growth factors (47) . Subsequent studies showed that amplification of the erbB2 gene is found in many types of cancers, and its overexpression is correlated with poor prognosis for breast and ovarian cancers (48 -50) . Although the importance of the erbB2 signaling in neural and cardiac development during embryogenesis has recently been established using erbB2-deficient mice (51), most of the information regarding the proposed functions of ErbB2 is derived from observations in transformed cells. Thus, limited information is available regarding its role in normal cell growth and development.
The highlights of the present investigation are that ErbB2 is expressed in a temporal and cell type-specific manner in the periimplantation uterus and that this receptor subtype could be influenced by ovarian steroid hormones. Another important finding is that the erbB2 gene is expressed predominantly in uterine epithelial cells. This finding is contrary to the observation that ErbB1 was not detected in these cells (7, 35) . The present results thus point toward the possibility that uterine epithelial cells could be the direct targets for EGF-like growth factors and may explain the controversy regarding the mechanism of EGF-induced uterine epithelial cell proliferation in vitro and in vivo (7, (33) (34) (35) . However, it should be recognized that for EGF-like ligands to be effective in mediating signal transduction via ErbB2 apparently requires the presence of another member of the erbB gene   FIG. 8 . Quantitation of rPL7 mRNA levels in steroid-treated adult ovariectomized mice. Quantitation of rPL7 mRNA was used as a control (housekeeping mRNA) for quantitation of the uterine erbB2 mRNA after steroid treatments. Treatment schedules were same as those described in Fig. 7 . Uterine total RNAs (8.75 g) were reverse transcribed using an rPL7 mRNA specific antisense oligo. A constant amount of the sample cDNA (one tenth of the total RT product) and increasing amounts of the competitor template (1-10,000 pg) were coamplified by PCR for 35 cycles using the antisense and sense oligos. The products were subjected to Southern blot hybridization using a 32 P-labeled internal oligo. Quantitation of rPL7 mRNA levels followed the procedure described in Fig. 7 . No significant changes in the levels of uterine rPL7 mRNA for each steroid treatment were noted; a representative plot for the P 4 -treated group is shown. These experiments were performed in triplicate. Values (nϭ3) are mean Ϯ SEM and were calculated as described in the legend to Fig. 7.   FIG. 9 . In situ hybridization of the erbB2 mRNA in steroid-treated adult ovariectomized uterus. Ovariectomized mice were given a single injection of oil (0.1 ml/mouse), E 2 (250 ng/mouse), P 4 (2 mg/mouse), or E 2 with P 4 . They were killed 24 h later. Darkfield photomicrographs of representative longitudinal uterine sections are shown. A, Oil injection (control); B, E 2 injection. These experiments were repeated with three mice in each treatment group with similar results.
family (see Fig. 10 ) (36) . The current model for the signaling of EGF-like growth factors and their receptors is as follows. Upon ligand binding, either heterodimerization or homodimerization of the receptors occurs, followed by receptor autophosphorylation. These autophosphorylation sites then create docking sites for downstream signal transduction molecules containing Src homology 2 domains (24). Although ErbB2 was formerly considered an orphan receptor, recent studies using different mammalian cell lines demonstrate that heterodimerization of ErbB2 with other subtypes is favored as the physiological receptors for NDF and EGF (37) . Our demonstration of phosphorylation of ErbB2 in whole uterine membrane preparations by several ligands suggests interaction of ErbB2 with other known or as yet unidentified subtypes of the ErbB family coexpressed in specific uterine cell types or transphosphorylation of ErbB2 by other membrane-associated nonreceptor kinases. Although ErbB1/ EGF-R is not present in uterine epithelial cells, we have preliminary evidence for the presence of ErbB4 in these cell types (unpublished), suggesting heterodimerization of ErbB2 with ErbB4 upon ligand binding that may influence epithelial cell functions in the absence of ErbB1/EGF-R. Indeed, we have evidence that the periimplantation mouse uterus expresses NDF and betacellulin in a cell-specific and temporal manner (unpublished observations). Thus, it is possible that EGF-like ligands of epithelial, stromal, or embryonic origin may modulate epithelial cell functions via interaction with epithelial cell ErbB2 and other receptor subtypes. However, the stromal cell-mediated modulation of epithelial cell functions by EGF or estrogen in a paracrine manner cannot be ruled out. Paracrine interactions between stromal and epithelial cells in the mouse uterus has again been demonstrated using estrogen receptor (ER) knock-out (ERKO) mice (52) . In this study, it was shown that E 2 treatment induced proliferation of ER-negative epithelial cells when they were reconstituted with ER-positive stromal cells. In contrast, E 2 failed to induce proliferation of ER-positive epithelial cells reconstituted with ER-negative stromal cells. These results strongly suggest indirect effects of E 2 on epithelial cell mitogenesis via modulation of stromal cell functions.
The profile of erbB2 mRNA expression is consistent with the pattern of uterine cell proliferation during the periimplantation period (3). In the preimplantation uterus, erbB2 is confined to the luminal and glandular epithelium, suggesting its possible involvement in epithelial cell proliferation and differentiation during this period. Although the significance of compartmentalized expression of ErbB1 and ErbB2 in the uterus is not clear, it is possible that differential modulation of epithelial and stromal cell functions by specific EGF-like molecules requires different signaling mechanisms that are accomplished via this compartmentalization of the receptors and/or ligands. The expression of erbB2 in the decidualizing stroma surrounding the blastocyst suggests that this receptor subtype is available for interaction with EGF-like ligands in the process of stromal cell proliferation and/or differentiation to decidual cells. On days 7 and 8, the trophoblastic giant cells of the embryo at the fetal-maternal interface exhibit accumulation of the erbB2 mRNA. As there is evidence that the oncogenically activated erbB2 gene may contribute to the invasion and spread of tumors (48), regulated expression of the ErbB2 in trophoblastic giant cells could be important for trophoblast invasion in the endometrium for the establishment of pregnancy. Although the importance of erbB2 expression in the epithelium at the interimplantation sites is not presently clear, it may participate in the elongation and differential growth of the uterus required for completion of embryo spacing (53) .
The higher levels of erbB2 mRNA expression in the day 1 uterus suggest possible up-regulation of this gene by preovulatory estrogen (3). This is consistent with our observation of up-regulation of this mRNA in the ovariectomized uterine epithelium by E 2 . It is interesting to note that P 4 not only antagonized the E 2 induction, but also down-regulated the constitutive (oil-treated) levels of the erbB2 mRNA in the uterus. These results are contrary to our observation of upregulation of the uterine erbB1 mRNA by E 2 , P 4 , or a combination of E 2 plus P 4 (7) . Thus, expression of the erbB2 gene in the uterus from day 4 onward appears not to be under the regulation of rising P 4 levels. Whether embryonic or other factors influence the expression of this gene in the uterus at the time of implantation and thereafter will require further investigation.
